| Filed On | Filing |
|---|---|
| 29 Oct 2026 |
8-K: Results of Operations and Financial Condition
ALAMEDA, Calif. – October 29, 2026 - Exelixis, Inc. (Nasdaq: EXEL) today reported financial results for the third quarter of 2026, provided an update on progress toward achieving key corporate objectives, and outlined its commercial, cli... |
| 11 Sep 2026 |
8-K: Other Events
Today, Exelixis, Inc. (Exelixis) announced that on September 10, 2026, the U.S. Food and Drug Administration (FDA) notified Exelixis that it had extended the review period for Exelixis’ new drug application (NDA) for zanzalintinib, in co... |
| 31 Aug 2026 |
8-K: Other Events
On August 31, 2026, Exelixis, inc. (Exelixis) announced that the U.S. Court of Appeals for the Federal Circuit (Court of Appeals) issued a decision in Exelixis, Inc. v. MSN Laboratories Private Limited et al., Appeal No. 25-1236, affirmi... |
| 05 Aug 2026 |
8-K: Results of Operations and Financial Condition
ALAMEDA, Calif. – August 5, 2026 - Exelixis, Inc. (Nasdaq: EXEL) today reported financial results for the second quarter of 2026, provided an update on progress toward achieving key corporate objectives, and outlined its commercial, clin... |
| 29 May 2026 |
8-K: Departure/Election of Directors or Officers; Compensation; Submission of Matters to a Vote of Security Holders
Adopted by the Board of Directors: February 23, 2017Amended by the Compensation Committee: March 22, 2017Approved by the Stockholders: May 24, 2017Amended by the Company: December 18, 2017Amended by the Compensation Committee: March 18, ... |
| 05 May 2026 |
8-K: Results of Operations and Financial Condition; Other Events
ALAMEDA, Calif. – May 5, 2026 - Exelixis, Inc. (Nasdaq: EXEL) today reported financial results for the first quarter of 2026, provided an update on progress toward achieving key corporate objectives, and outlined its commercial, clinical... |
| 10 Feb 2026 |
8-K: Results of Operations and Financial Condition
- Cabozantinib Franchise Achieved $2.123 billion in U.S. Net Product Revenues for the Fiscal Year 2025, including $547 million for the Fourth Quarter of 2025 - |
| 12 Jan 2026 |
8-K: Results of Operations and Financial Condition
Exelixis Announces Preliminary Fiscal Year 2025 Financial Results, Provides 2026 Financial Guidance and Outlines Key Priorities and Milestones for 2026 |
| 07 Nov 2025 |
8-K: Departure/Election of Directors or Officers; Compensation; Other Events
On November 4, 2025, Jeffrey Hessekiel, J.D., Executive Vice President and General Counsel of Exelixis, Inc. (the Company) notified the Company of his intention to resign from the Company, effective in November 2025, and he will cease se... |
| 04 Nov 2025 |
8-K: Results of Operations and Financial Condition; Other Events
ALAMEDA, Calif. – November 4, 2025 - Exelixis, Inc. (Nasdaq: EXEL) today reported financial results for the third quarter of 2025, provided an update on progress toward achieving key corporate objectives, and outlined its commercial, cli... |
| 29 Aug 2025 |
8-K: Departure/Election of Directors or Officers; Compensation
On August 29, 2025, the Board of Directors (the “Board”) of Exelixis, Inc. (the “Company”) appointed Dana T. Aftab, Ph.D., the Company’s current Executive Vice President, Discovery and Translational Research and Chief Scientific Officer ... |
| 28 Jul 2025 |
8-K: Results of Operations and Financial Condition
ALAMEDA, Calif. – July 28, 2025 - Exelixis, Inc. (Nasdaq: EXEL) today reported financial results for the second quarter of 2025, provided an update on progress toward achieving key corporate objectives, and outlined its commercial, clini... |
| 02 Jun 2025 |
8-K: Submission of Matters to a Vote of Security Holders
(a) On May 28, 2025, Exelixis held its Annual Meeting via live webcast. |
| 13 May 2025 |
8-K: Results of Operations and Financial Condition
ALAMEDA, Calif. – May 13, 2025 - Exelixis, Inc. (Nasdaq: EXEL) today reported financial results for the first quarter of 2025, provided an update on progress toward achieving key corporate objectives, and outlined its commercial, clinica... |
| 31 Mar 2025 |
8-K: Departure/Election of Directors or Officers; Compensation
On March 28, 2025, the Board of Directors (Board) of Exelixis, Inc. (Company) approved, following a recommendation of the Compensation Committee of the Board (Compensation Committee), a program providing for a special one-time performanc... |
| 21 Feb 2025 |
8-K: Other Events
- Completion of currently ongoing stock repurchase program expected in the second quarter of 2025 - |
| 11 Feb 2025 |
8-K: Results of Operations and Financial Condition
- Cabozantinib Franchise Achieved $1.81 billion in U.S. Net Product Revenues for the Fiscal Year 2024, including $515 million for the Fourth Quarter of 2024 - |
| 13 Jan 2025 |
8-K: Results of Operations and Financial Condition
Exelixis Announces Preliminary Fiscal Year 2024 Financial Results, Provides 2025 Financial Guidance and Outlines Key Priorities and Milestones for 2025 |
| 29 Oct 2024 |
8-K: Results of Operations and Financial Condition
ALAMEDA, Calif. – October 29, 2024 - Exelixis, Inc. (Nasdaq: EXEL) today reported financial results for the third quarter of 2024, provided an update on progress toward achieving key corporate objectives, and detailed its recent and anti... |
| 15 Oct 2024 |
8-K: Other Events
On October 15, 2024, Exelixis, Inc. (Exelixis) announced that the U.S. District Court for the District of Delaware (the Delaware District Court) issued a ruling in our two consolidated patent lawsuits against MSN Pharmaceuticals, Inc. (i... |
Loading...